NASDAQ: AZRX

SEARCH

SIGN UP

AzurRx Logo
  • About
      • Back
      • Company Profile
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
  • Science & Technology
      • Back
      • Overview
      • Programs
      • Development Pipeline
      • Cystic Fibrosis
      • Chronic Pancreatitis
      • Immune Checkpoint Inhibitor Colitis
      • COVID-19 GI Infections
      • Non-Systemic Biologics
      • Digestive Enzymes
      • Niclosamide
  • Investors
      • Back
      • Press Releases
          • Back
          • 2021
          • 2020
          • 2019
          • 2018
          • 2017
          • 2016
          • 2015
          • 2014
      • Events
      • Presentations
      • Regulatory Filings
      • Financial Statements
          • Back
          • 2020
              • Back
              • Q2 2020
              • Q1 2020
          • 2019
              • Back
              • Q4 2019
              • Q3 2019
              • Q2 2019
              • Q1 2019
          • 2018
              • Back
              • Q4 2018
              • Q3 2018
              • Q2 2018
              • Q1 2018
          • 2017
              • Back
              • Q4 2017
              • Q3 2017
              • Q2 2017
              • Q1 2017
          • 2016
              • Back
              • Q4 2016
              • Q3 2016
      • Stock Info
      • Analyst Coverage
      • Corporate Governance
      • Contact Us
  • News and Media
      • Back
      • Podcasts
      • Media Interviews
  • Clinical Trials
      • Back
      • Ongoing Clinical Trials
      • Completed Clinical Trials
      • Clinical Publications
  • Collaborations
      • Back
      • Partnering with AzurRx
  • Contact
      • Back
      • Contact Us
      • Subscribe
  • Home
  • Investors
  • Press Releases
  • 2016

Menu

  • Press Releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
  • Events
  • Presentations
  • Regulatory Filings
  • Financial Statements
    • 2020
      • Q2 2020
      • Q1 2020
    • 2019
      • Q4 2019
      • Q3 2019
      • Q2 2019
      • Q1 2019
    • 2018
      • Q4 2018
      • Q3 2018
      • Q2 2018
      • Q1 2018
    • 2017
      • Q4 2017
      • Q3 2017
      • Q2 2017
      • Q1 2017
    • 2016
      • Q4 2016
      • Q3 2016
  • Stock Info
  • Analyst Coverage
  • Corporate Governance
  • Contact Us

2016 News

Filters
List of articles in category 2016 News
Title Date
AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference 28 Dec, 2016
AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Exocrine Pancreatic Insufficiency 21 Dec, 2016
WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma 12 Dec, 2016
AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology 06 Dec, 2016
AzurRx CEO Provides Shareholders With a "State of the Union" Communication 01 Dec, 2016
AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event 30 Nov, 2016
AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients 17 Nov, 2016
AzurRx BioPharma Inc. (Nasdaq: AZRX) to Ring The Nasdaq Stock Market Closing Bell 19 Oct, 2016
AzurRx BioPharma Announces Pricing of Initial Public Offering 11 Oct, 2016
  • About
  • Science & Technology
  • Investors
  • News and Media
  • Clinical Trials
  • Collaborations
  • Contact

Contact Us

AzurRx BioPharma, Inc.

1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445 

Tel: 646-699-7855
info@azurrx.com

AzurRx SAS

Jardin des Entreprises, Bat 1
290, Chemin de Saint-Dionisy
30980 Langlade, France

Tel: +33 (0)4 66 67 08 16

SiteMap Ⓒ 2021 AzurRx All Rights Reserved.